Terms: = Ovarian cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
17 results:
1. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract] [Full Text] [Related]
3. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.
Schadeck J; Oberg HH; Peipp M; Hedemann N; Schamel WW; Bauerschlag D; Wesch D
Front Immunol; 2023; 14():1286097. PubMed ID: 38259448
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
Han X; Yang L; Tian H; Ji Y
Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
[TBL] [Abstract] [Full Text] [Related]
6. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract] [Full Text] [Related]
7. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
8. cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract] [Full Text] [Related]
9. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of ovarian cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract] [Full Text] [Related]
10. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
[TBL] [Abstract] [Full Text] [Related]
11. pd-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
[TBL] [Abstract] [Full Text] [Related]
12. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract] [Full Text] [Related]
13. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
Wolf D; Fiegl H; Zeimet AG; Wieser V; Marth C; Sprung S; Sopper S; Hartmann G; Reimer D; Boesch M
Int J Cancer; 2020 Apr; 146(7):2007-2018. PubMed ID: 31800094
[TBL] [Abstract] [Full Text] [Related]
14. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
[TBL] [Abstract] [Full Text] [Related]
15. Immune Checkpoint Inhibitors in Gynecological cancers: Update of Literature and Perspectives of clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract] [Full Text] [Related]
16. The effect of polymorphisms in pd-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
Li Y; Zhang HL; Kang S; Zhou RM; Wang N
Gynecol Oncol; 2017 Jan; 144(1):140-145. PubMed ID: 27836206
[TBL] [Abstract] [Full Text] [Related]
17. Anti-PD-L1/pd-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract] [Full Text] [Related]
